Comparative Pharmacology
Head-to-head clinical analysis: BENZOYL PEROXIDE AND CLINDAMYCIN PHOSPHATE versus CLEOCIN PHOSPHATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENZOYL PEROXIDE AND CLINDAMYCIN PHOSPHATE versus CLEOCIN PHOSPHATE.
BENZOYL PEROXIDE AND CLINDAMYCIN PHOSPHATE vs CLEOCIN PHOSPHATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Benzoyl peroxide: oxidizes bacterial proteins via free radical release, reducing Cutibacterium acnes; keratolytic and comedolytic. Clindamycin phosphate: inhibits bacterial protein synthesis by binding to 50S ribosomal subunit, bacteriostatic against C. acnes.
Clindamycin phosphate is a prodrug that is hydrolyzed to clindamycin. Clindamycin binds to the 50S subunit of bacterial ribosomes, inhibiting protein synthesis. It exhibits bacteriostatic activity against susceptible bacteria.
Topical: Apply a thin film to affected areas twice daily (morning and evening). Each gram of gel contains 50 mg benzoyl peroxide and 10 mg clindamycin phosphate (as clindamycin).
600-2700 mg/day IV/IM in 2-4 divided doses. Typical: 600-900 mg IV q8h or 300-600 mg IM q12h.
None Documented
None Documented
Clindamycin terminal elimination half-life is 2-4 hours in adults; benzoyl peroxide has minimal systemic absorption, so half-life is not clinically relevant.
Terminal elimination half-life is 2-3 hours in adults with normal renal and hepatic function; may be prolonged to 4-5 hours in patients with severe hepatic impairment (Child-Pugh C). In neonates, half-life ranges from 8-12 hours, decreasing to adult values by 1 month of age.
Benzoyl peroxide is metabolized to benzoic acid, which is excreted in urine as hippuric acid; clindamycin phosphate is hydrolyzed to clindamycin, which undergoes hepatic metabolism with about 10% excreted unchanged in urine, 3.6% in feces as active drug, and the remainder as metabolites.
Approximately 10% as active drug and metabolites in urine, 3.6% in feces; major route is hepatic metabolism to inactive metabolites (N-demethylclindamycin and clindamycin sulfoxide) excreted in bile and feces. Renal excretion accounts for about 10% of the dose, with the remainder eliminated via biliary/fecal route.
Category A/B
Category C
Lincosamide Antibiotic
Lincosamide Antibiotic